Physician profile
Scott J Rhamy
NPI 1346240827
$2,169.71
in general payments reported to CMS, 2019-2025
30 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $517 · 2021: $148 · 2022: $137 · 2023: $348 · 2024: $482 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $567.07 | 2020-2025 | |
| Astellas Pharma US INC | $363.39 | 2019-2025 | Xtandi, Myrbetriq |
| Blue Earth Diagnostics | $155.09 | 2020-2025 | Posluma |
| Sumitomo Pharma America, INC. | $112.20 | 2023-2025 | Orgovyx, Gemtesa |
| Neotract INC. | $100.01 | 2020 | |
| Amgen INC. | $97.03 | 2020-2022 | |
| Dendreon Pharmaceuticals LLC | $87.29 | 2019-2021 | |
| Allergan, INC. | $64.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $55.80 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $54.79 | 2022 | |
| Merck Sharp & Dohme LLC | $54.56 | 2020 | |
| Endo Pharmaceuticals INC. | $40.68 | 2020 | |
| Teleflex LLC | $40.52 | 2021-2023 | Urolift |
| Janssen Biotech, INC. | $34.84 | 2020-2023 | |
| Ambu INC. | $34.72 | 2022-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $31.47 | 2019-2024 | Resonance |
| Procept Biorobotics Corporation | $29.55 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Urogen Pharma, INC. | $27.01 | 2020 | |
| Antares Pharma, INC. | $26.23 | 2020 | |
| Endo USA, INC. | $24.55 | 2025 | Xiaflex |
| Genzyme Corporation | $21.83 | 2023 | |
| Ferring Pharmaceuticals INC. | $21.07 | 2024 | Adstiladrin |
| Travere Therapeutics, INC. | $18.93 | 2020 | |
| Cardinal Health 414 LLC | $18.89 | 2022 | |
| Olympus America INC. | $18.83 | 2025 | Itind System |
| Rochester Medical Corporation | $16.55 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.26 | 2022 | |
| Foundation Medicine, INC. | $13.69 | 2021 | |
| Clovis Oncology, INC. | $12.09 | 2020 | |
| Pfizer INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rhamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.